Rhythm Biosciences Ltd has released a press release.
RHY Platform Technology Targets Five Cancers
Filed with ASX ·
6ix hasn’t read this filing yet.
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Board and Management Restructure
- CE Mark Granted for ColoSTAT
- Change of Director's Interest Notice x 4
- Application for quotation of securities - RHY
- RHY - Institutional Investor Presentation
Later from Rhythm Biosciences
- Placement of $6.5m to Global Institutional Funds Manager
- Rhythm Maintains Ongoing ISO13485 Certification
- Appendix 4D and Half Yearly Report and Accounts
- Rhythm Biosciences - Investor Webinar Presentation
- S&P DJI Announces March 2022 Quarterly Rebalance
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences